



CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16
REPORTED :07/02/2023 15:20:19

10,7,62,2023 13.20.13

Test Report Status <u>Final</u> Results Biological Reference Interval Units

| н | HAEMATOLOGY - CBC | | | | | |
|--|-------------------|----------------|-----------------|--|--|--|
| MEDI WHEEL FULL BODY HEALTH CHECKUP AB | OVE 40FEMALE | | | | | |
| BLOOD COUNTS,EDTA WHOLE BLOOD | | | | | | |
| HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION | 12.5 | 12.0 - 15.0 | g/dL | | | |
| RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE | 4.49 | 3.8 - 4.8 | mi l /μL | | | |
| WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE | 10.20 High | 4.0 - 10.0 | thou/µL | | | |
| PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE | 262 | 150 - 410 | thou/µL | | | |
| RBC AND PLATELET INDICES | | | | | | |
| HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER | 39.2 | 36 - 46 | % | | | |
| MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER | 87.0 | 83 - 101 | fL | | | |
| MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER | 27.9 | 27.0 - 32.0 | pg | | | |
| MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER | 32.0 | 31.5 - 34.5 | g/dL | | | |
| RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER | 14.1 High | 11.6 - 14.0 | % | | | |
| MENTZER INDEX | 19.4 | | | | | |
| MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER | 9.3 | 6.8 - 10.9 | fL | | | |
| WBC DIFFERENTIAL COUNT | | | | | | |
| NEUTROPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY | 69 | 40 - 80 | % | | | |
| LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY | 24 | 20 - 40 | % | | | |
| MONOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY | 03 | 2 - 10 | % | | | |
| EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY | 04 | 1 - 6 | % | | | |

Dr. Akansha 1

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 15













CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB000467 PATIENT ID : ASHAF070274251 CLIENT PATIENT ID: 012302070015

ABHA NO

AGE/SEX :49 Years Female :07/02/2023 09:11:00 DRAWN RECEIVED: 07/02/2023 10:50:16 REPORTED :07/02/2023 15:20:19

| Test Report Status <u>Final</u> | Results | Biological Reference | Biological Reference Interval Units | | |
|--|--------------------|----------------------|-------------------------------------|--|--|
| BASOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY | 00 | 0 - 2 | % | | |
| ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER | 7 . 04 High | 2.0 - 7.0 | thou/μL | | |
| ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER | 2.45 | 1.0 - 3.0 | thou/µL | | |
| ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER | 0.31 | 0.2 - 1.0 | thou/µL | | |
| ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER | 0.41 | 0.02 - 0.50 | thou/µL | | |
| ABSOLUTE BASOPHIL COUNT | 0 Low | 0.02 - 0.10 | thou/µL | | |
| NEUTROPHIL LYMPHOCYTE RATIO (NLR) | 2.9 | | | | |

from Beta thalassaemia trait

Interpretation(s)
BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 15













CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID : ASHAF070274251

CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00

RECEIVED : 07/02/2023 10:50:16 REPORTED : 07/02/2023 15:20:19

Test Report Status <u>Final</u> Results Biological Reference Interval Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 15 0 - 20 mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates) REFERENCE

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis 10th edition.

Dr. Akansha Jain Consultant Pathologist Page 3 Of 15





View Details





CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB000467 PATIENT ID : ASHAF070274251

CLIENT PATIENT ID: 012302070015

AGE/SEX :49 Years :07/02/2023 09:11:00 DRAWN RECEIVED: 07/02/2023 10:50:16

REPORTED :07/02/2023 15:20:19

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

ABHA NO

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE B

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist** Page 4 Of 15















CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16
REPORTED :07/02/2023 15:20:19

Test Report Status Final Results Biological Reference Interval Units

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE

BLOOD

HBA1C **6.0 High** Non-diabetic: < 5.7 %

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)

ESTIMATED AVERAGE GLUCOSE(EAG) 125.5 High < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) **103 High** 74 - 99 mg/dL

METHOD: GLUCOSE OXIDASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 112 70 - 140 mg/dL

METHOD : GLUCOSE OXIDASE

LIPID PROFILE, SERUM

CHOLESTEROL, TOTAL **207 High** < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD : CHOLESTEROL OXIDASE

TRIGLYCERIDES

90 < 150 Normal mg/dL

150 - 199 Borderline High

200 - 499 High >/=500 Very High

>/=500 Very High

HDL CHOLESTEROL 55 < 40 Low mg/dL

>/=60 High

METHOD : DIRECT CLEARANCE METHOD

Dr. Akansha Jain Consultant Pathologist



Page 5 Of 15











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16
REPORTED :07/02/2023 15:20:19

| | | L | |
|---|--------------------|--|---------|
| Test Report Status <u>Final</u> | Results | Biological Reference Interva | l Units |
| CHOLESTEROL LDL | 134 High | < 100 Optimal 100 - 129 Near optimal/ above optima 130 - 159 Borderline High 160 - 189 High >/= 190 Very High | mg/dL |
| NON HDL CHOLESTEROL | 152 High | Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220 | mg/dL |
| METHOD: CALCULATED PARAMETER | | | |
| VERY LOW DENSITY LIPOPROTEIN | 18.0 | = 30.0</td <td>mg/dL</td> | mg/dL |
| CHOL/HDL RATIO | 3.8 | 3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk | |
| LDL/HDL RATIO | 2.4 | 0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk | |
| Interpretation(s) | | | |
| LIVER FUNCTION PROFILE, SERUM | | | |
| BILIRUBIN, TOTAL METHOD: DIAZO WITH SULPHANILIC ACID | 1.00 | 0 - 1 | mg/dL |
| BILIRUBIN, DIRECT METHOD: DIAZO WITH SULPHANILIC ACID | 0 . 33 High | 0.00 - 0.25 | mg/dL |
| BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER | 0.67 | 0.1 - 1.0 | mg/dL |
| TOTAL PROTEIN METHOD: BIURET REACTION, END POINT | 7.7 | 6.4 - 8.2 | g/dL |
| ALBUMIN | 4.1 | 3.8 - 4.4 | g/dL |

Dr. Akansha Jain Consultant Pathologist





Page 6 Of 15

View Details











CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16
REPORTED :07/02/2023 15:20:19

| Test Report Status <u>Final</u> | Results | Biological Reference | Biological Reference Interval Units | | |
|---|----------------|----------------------|-------------------------------------|--|--|
| | | | | | |
| METHOD : BROMOCRESOL GREEN | 2.6 | 20 41 | a/dl | | |
| GLOBULIN METHOD: CALCULATED PARAMETER | 3.6 | 2.0 - 4.1 | g/dL | | |
| | 1.1 | 1.0 - 2.1 | RATIO | | |
| ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER | 1.1 | 1.0 - 2.1 | KATIO | | |
| ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C | 19 | 0 - 31 | U/L | | |
| ALANINE AMINOTRANSFERASE (ALT/SGPT) | 28 | 0 - 31 | U/L | | |
| METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37° C ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C | 68 | 39 - 117 | U/L | | |
| GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYL-3 CARBOXY-4 NITROANILIDE (IFCC | 39 High | 7 - 32 | U/L | | |
| LACTATE DEHYDROGENASE | 297 | 230 - 460 | U/L | | |
| BLOOD UREA NITROGEN (BUN), SERUM | | | | | |
| BLOOD UREA NITROGEN METHOD: UREASE KINETIC | 8 | 5.0 - 18.0 | mg/dL | | |
| CREATININE, SERUM | | | | | |
| CREATININE | 0.80 | 0.6 - 1.2 | mg/dL | | |
| METHOD: ALKALINE PICRATE NO DEPROTEINIZATION | | | | | |
| BUN/CREAT RATIO | | | | | |
| BUN/CREAT RATIO | 10.00 | | | | |
| METHOD: CALCULATED PARAMETER | | | | | |
| URIC ACID, SERUM | | | | | |
| URIC ACID | 5.1 | 2.4 - 5.7 | mg/dL | | |
| METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE | | | | | |
| TOTAL PROTEIN, SERUM | | | | | |
| TOTAL PROTEIN METHOD: BIURET REACTION, END POINT | 7.7 | 6.4 - 8.3 | g/dL | | |
| ALBUMIN, SERUM | | | | | |
| ALBUMIN | 4.1 | 3.8 - 4.4 | g/dL | | |
| METHOD: BROMOCRESOL GREEN | | | - | | |
| GLOBULIN | | | | | |
| GLOBULIN | 3.6 | 2.0 - 4.1 | g/dL | | |

Or Akansha lai

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 15

View Details











REF. DOCTOR: SELF **PATIENT NAME: ASHA UMARWAL**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB000467 PATIENT ID : ASHAF070274251 CLIENT PATIENT ID: 012302070015

ABHA NO

AGE/SEX :49 Years Female DRAWN :07/02/2023 09:11:00 RECEIVED: 07/02/2023 10:50:16 REPORTED: 07/02/2023 15:20:19

| Test Report Status <u>Final</u> | Results | Biological Reference | Interval Units |
|---|-----------|----------------------|-----------------|
| ELECTROLYTES (NA/K/CL), SERUM | | | |
| SODIUM, SERUM | 136.6 Low | 137 - 145 | mmo l /L |
| METHOD : ION-SELECTIVE ELECTRODE POTASSIUM, SERUM | 4.33 | 3.6 - 5.0 | mmo l /L |
| METHOD: ION-SELECTIVE ELECTRODE CHLORIDE, SERUM | 102.5 | 98 - 107 | mmo l /L |
| METHOD: ION-SELECTIVE ELECTRODE | 102.5 | 30 107 | Timoy E |

Interpretation(s)

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.

3.Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

- 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels. 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results. IV. Interference of hemoglobinopathies in HbA1c estimation is seen in a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides.

Decreased in

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE:

while random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Dr. Akansha Jain **Consultant Pathologist**





Page 8 Of 15

View Report











CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

<u>Fina</u>

JAIPUR 302017 9314660100

Test Report Status

ACCESSION NO: 0251WB000467 PATIENT ID : ASHAF070274251 CLIENT PATIENT ID: 012302070015

ABHA NO

AGE/SEX :49 Years Female DRAWN :07/02/2023 09:11:00 RECEIVED: 07/02/2023 10:50:16 REPORTED: 07/02/2023 15:20:19

Results Biological Reference Interval Units

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin wiral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that

attaches sugar molecules to bilirubin.
AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget'''s disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson'''s disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom'''s disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma.It is produced in the liver Albumin constitutes about half of the blood serum protein.Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- · Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia GravisMuscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom""""""" disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum

protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 9 Of 15













CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB000467 PATIENT ID : ASHAF070274251 CLIENT PATIENT ID: 012302070015

ABHA NO

AGE/SEX :49 Years Female :07/02/2023 09:11:00 DRAWN RECEIVED: 07/02/2023 10:50:16

REPORTED: 07/02/2023 15:20:19

Test Report Status Results **Biological Reference Interval Units** <u>Final</u>

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION, URINE

COLOR PALE YELLOW

METHOD: GROSS EXAMINATION

CLEAR **APPEARANCE**

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PΗ 5.0 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY <=1.005 1 003 - 1 035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN NOT DETECTED NOT DETECTED

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

NOT DETECTED NOT DETECTED

METHOD: GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

NOT DETECTED NOT DETECTED KETONES

METHOD: SODIUM NITROPRUSSIDE REACTION

NOT DETECTED NOT DETECTED **BLOOD**

METHOD: PEROCIDASE ANTI PEROXIDASE

NOT DETECTED NOT DETECTED **BILIRUBIN** METHOD : DIPSTICK

UROBILINOGEN

NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

NOT DETECTED LEUKOCYTE ESTERASE NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

/HPF RED BLOOD CELLS NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 0-5 /HPF 1-2

METHOD: DIPSTICK, MICROSCOPY 0-5 /HPF EPITHELIAL CELLS 3-5

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **CASTS**

Dr. Akansha Jain **Consultant Pathologist**



Page 10 Of 15









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251

CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16

REPORTED :07/02/2023 15:20:19

Test Report Status Final Results Biological Reference Interval Units

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

YEAST NOT DETECTED NOT DETECTED

Interpretation(s)

Dr. Akansha Jain Consultant Pathologist



Page 11 Of 15

View Details







CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251

CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female DRAWN :07/02/2023 09:11:00

RECEIVED : 07/02/2023 10:50:16 REPORTED :07/02/2023 15:20:19

Test Report Status Final Results Biological Reference Interval Units

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD SAMPLE NOT RECEIVED

Dr. Akansha Jain Consultant Pathologist



Page 12 Of 15













CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB000467**PATIENT ID : ASHAF070274251

CLIENT PATIENT ID: 012302070015

ABHA NO

AGE/SEX :49 Years Female DRAWN :07/02/2023 09:11:00 RECEIVED :07/02/2023 10:50:16

REPORTED :07/02/2023 15:20:19

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION,STOOL COLOUR

METHOD: GROSS EXAMINATION

SAMPLE NOT RECEIVED

Dr. Abhishek Sharma

Consultant Microbiologist



Page 13 Of 15

View Details









CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

DRAWN :07/02/2023 09:11:00 RECEIVED :07/02/2023 10:50:16 REPORTED :07/02/2023 15:20:19

:49 Years

AGE/SEX

Test Report Status <u>Final</u> Results Biological Reference Interval Units

ABHA NO

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

| T3 METHOD: CHEMILUMINESCENCE | 114.99 | 60.0 - 181.0 | ng/dL |
|-------------------------------|--------|---------------|--------|
| T4 METHOD: CHEMILUMINESCENCE | 6.60 | 4.5 - 10.9 | μg/dL |
| TSH (ULTRASENSITIVE) | 3.557 | 0.550 - 4.780 | μIU/mL |

Interpretation(s)

Triiodothyronine T3, **Thyroxine T4**, and **Thyroid Stimulating Hormone TSH** are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low. owidetlparowidetlparBelow mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

| Sr. No. | TSH | Total T4 | FT4 | Total T3 | Possible Conditions |
|---------|------------|----------|--------|----------|--|
| 1 | High | Low | Low | Low | (1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) |
| | | | | | Post Thyroidectomy (4) Post Radio-Iodine treatment |
| 2 | High | Normal | Normal | Normal | (1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid |
| | | | | | hormone replacement therapy (3) In cases of Autoimmune/Hashimoto |
| | | | | | thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical |
| | | | | | inflammation, drugs like amphetamines, Iodine containing drug and |
| | | | | | dopamine antagonist e.g. domperidone and other physiological reasons. |
| 3 | Normal/Low | Low | Low | Low | (1) Secondary and Tertiary Hypothyroidism |
| 4 | Low | High | High | High | (1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre |
| | | | | | (3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid |
| | | | | | hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 |
| | | | | | replacement therapy (7) First trimester of Pregnancy |
| 5 | Low | Normal | Normal | Normal | (1) Subclinical Hyperthyroidism |
| 6 | High | High | High | High | (1) TSH secreting pituitary adenoma (2) TRH secreting tumor |
| 7 | Low | Low | Low | Low | (1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent |
| | | | | | treatment for Hyperthyroidism |

Dr. Akansha Jain Consultant Pathologist



Page 14 Of 15









CODE/NAME & ADDRESS : C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB000467**PATIENT ID: ASHAF070274251
CLIENT PATIENT ID: 012302070015

ABHA NO :

AGE/SEX :49 Years Female
DRAWN :07/02/2023 09:11:00
RECEIVED :07/02/2023 10:50:16
REPORTED :07/02/2023 15:20:19

Test Report Status Final Results Biological Reference Interval Units

| 8 | Normal/Low | Normal | Normal | High | (1) T3 thyrotoxicosis (2) Non-Thyroidal illness |
|---|------------|--------|--------|--------|--|
| 9 | Low | High | High | Normal | (1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies |

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. **NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.**TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist





Page 15 Of 15









Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

| NAME | MRS ASHA UMARWAL | AGE | 49Y | SEX | FEMALE |
|------------------|--------------------------|------------|------------|--------|--------|
| REF BY | MEDIWHEEL | DATE | 07/02/2023 | REG NO | |
| | FCHOCAR | DIOGRAM RE | PORT | | |
| WINDO | N- POOR/ADEQUATE/GOODVAL | | ···· | | |
| WINDON MITRAL | | | | NORMA | |

2D/M-MOD

| IVSD mm | 9.5 | IVSS mm | 13.2 | AORTA mm | 23.3 |
|----------|------|----------|------|----------|------|
| LVID mm | 41.3 | LVIS mm | 24.4 | LA mm | 29.1 |
| LVPWD mm | 9.8 | LVPWS mm | 13.5 | EF% | 60% |

CHAMBERS

| LA | NORMAL | RA | NORMAL |
|-------------|--------|----|--------|
| LV | NORMAL | RV | NORMAL |
| PERICARDIUM | NORMAL | | |

DOPPLER STUDY MITRAL

| PEAK VELOCITY m/s E/A | 1.23/1.26 | PEAK GRADIANT MmHg | |
|------------------------|----------------|--|--|
| MEAN VELOCITY m/s | | MEAN GRADIANT MmHg | |
| MVA cm2 (PLANITMETERY) | -w905VIII | MVA cm2 (PHT) | |
| MR | 20241811000000 | The state of the s | |

AORTIC

| PEAK VELOCITY m/s | 1.99 | PEAK GRADIANT MmHg | |
|-------------------|------|--|--|
| MEAN VELOCITY m/s | | MEAN GRADIANT MmHg | |
| AR | | and the state of t | |

TRICUSPID

| TR TRACE | | PASP mmHg | |
|-------------------|----------|--------------------|--|
| MEAN VELOCITY m/s | ALC: NO. | MEAN GRADIANT MmHg | |
| PEAK VELOCITY m/s | 0.73 | PEAK GRADIANT MmHg | |

PULMONARY

| PEAK VELOCITY m/s 1.55 | | PEAK GRADIANT MmHg | |
|------------------------|--------|--------------------|--|
| MEAN VELOCITY m/s | | MEAN GRADIANT MmHg | |
| PR | - Prof | RVEDP mmHg | |

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- TRACE TR
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION: FAIR LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563



Name

: Ms. ASHA UMARWAL

Age/Gender: 49 Y/Female Patient ID : 012302070015

BarcodeNo : 10075535

Referred By: Self

Registration No: 51484

Registered : 07

: 07/Feb/2023 09:11AM

Analysed

: 07/Feb/2023 01:00PM

Reported

: 07/Feb/2023 01:00PM

Panel

· Medi Wheel (ArcoFemi

Healthcare Ltd)

DIGITAL X-RAY CHEST PA VIEW

Soft tissue shadow and bony cages are normal.

Trachea is central.

Bilateral lung field and both CP angle are clear.

Domes of diaphragm are normally placed.

Transverse diameter of heart appears with normal limits.

IMPRESSION:- NO OBVIOUS ABNORMALITY DETECTED.

wellness partner

*** End Of Report ***

Page 1 of 1



Dr. Ngera Mehta M.B.B.S., D.M.R.D. RMCNO.005807/14853



akriti Labs

Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name

: Ms. ASHA UMARWAL

Age/Gender: 49 Y/Female

Patient ID : 012302070015

BarcodeNo : 10075535

Referred By: Self

Registration No: 51484

Registered

: 07/Feb/2023 09:11AM

Analysed

: 07/Feb/2023 11:33AM

Reported

: 07/Feb/2023 11:33AM

Panel

: Medi Wheel (ArcoFemi

Healthcare Ltd)

USG: WHOLE ABDOMEN (Female)

LIVER

: Is normal in size, shape and echogenecity.

The IHBR and hepatic radicals are not dilated.

No evidence of focal echopoor/echorich lesion seen. Portal vein diameter and Common bile duct normal in size

GALL

: Is not visualized. H/o Cholecystectomy.

BLADDER

PANCREAS: Is normal in size, shape and echotexture. Pancreatic duct is not dilated. : Is normal in size shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Bilateral Kidneys are normal in size, shape and echotexture,

corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER: No evidence of mass or stone in bladder lumen.

UTERUS

: Uterus is anteverted with bulky in size and shape. Size: 86 x 64 x 42 mm.

Uterine muscular shadows normal echopattern.

Endometrium is normal and centrally placed with size:10 mm.

No evidence of mass lesion is seen.

ADNEXA :

Both the ovaries are normal in size shape and echotexture.

No mass lesion/ polycystic ovarian cyst is seen.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. NO evidence of lymphadenopathy or mass lesion in retroperitoneum.

Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION: Bulky uterus

*** End Of Report ***

Page 1 of 1

RMCNO.005807/14853

Dr. Neera Mehta M.B.B.S., D.M.R.D.



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Moc Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

| PATIENT NAME: MRS ASHA UMARWAL | | AGE: 49 Yrs. |
|--------------------------------|---|------------------|
| REF. by: MEDI WHEEL | • | DATE: 07/02/2023 |

Ultrasonography report: Breast and Axilla

Findings:

Right Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.

Fibroglandular tissue shows normal architecture and echotexture.

Pre and retromammary regions are unremarkable.

No obvious cyst, mass or architectural distortion visualized.

Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

Left Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.

Fibroglandular tissue shows normal architecture and echotexture.

Pre and retromammary regions are unremarkable.

No obvious cyst, mass or architectural distortion visualized.

Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

IMPRESSION: No abnormality detected.

DR NEERA MEHTA MBBS, DMRD

RMCNO.005807/14853